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Abstract 
Bevacizumab is considered an established part of the treatment strategies available for 
schwannomas in patients with Neurofibromatosis Type 2(NF2).  In the UK, it is 
available through NHS National Specialized Commissioning to NF2 patients with a 
rapidly growing target schwannoma. Regrowth of the tumour on suspension of 
treatment is often observed resulting in prolonged periods of exposure to 
bevacizumab to control the disease.  Hypertension and proteinuria are common events 
with bevacizumab use and there are concerns with regards to the long-term risks of 
prolonged treatment. 
Dosing, demographic and adverse event(CTCAE 4.03) data from the UK NF2 
bevacizumab cohort are reviewed with particular consideration of renal and 
cardiovascular complications. 
Eighty patients (48 male:32female), median age 24.5 years (range 11-66years), were 
followed for a median of 32.7 months (range 12.0–60.2months).  The most common 
adverse events were fatigue, hypertension and infection. A total of 19/80 patients 
(24%) had either a grade 2 or grade 3 hypertension event and 14/80 patients (17.5%) 
had proteinuria.  Of 36 patients followed for 36 months, 78% were free from 
hypertension and 86% were free of proteinuria.  Logistic regression modeling 
identified age and induction dosing regime to be predictors of development of 
hypertension with dose of 7.5mg/kg three weekly and age >30years having higher 
rates of hypertension.  Proteinuria persisted in one of three patients after cessation of 
bevacizumab.  One patient developed congestive heart failure and the details of this 
case are described. 
Further work is needed to determine optimal dosing regimes to limit toxicity without 
impacting on efficacy.
Introduction: 
Bevacizumab is now an established treatment option for Neurofibromatosis type 2 
(NF2) associated schwannomas in the UK, Europe and the United States, with over 
100 people being treated in the UK alone for rapidly growing schwannomas [1-8].  
People with NF2 can suffer significant morbidity and mortality due to their disease 
and life expectancy is substantially reduced in more severe cases [9]. A reduction in 
size of cystic structures associated with a small group of ependymomas has also been 
reported [10,11](Morris et al 2016 submitted).  Meningiomas while common in NF2 
have been shown to respond to bevacizumab only briefly and only in a small minority 
of cases.[12,13] 
  
Radiological response rates for schwannomas have been approximately 35-40% in all 
reported adult cohorts. The optimal timing and duration of treatment are yet to be 
identified.  Longer breaks in treatment have been associated with tumour regrowth in 
some cases [3,6].  Therefore, once tumour growth has been controlled, UK practice 
has been to maintain tumour stability using a reduced dose intensity 'maintenance' 
regimen [6]. This approach has also been successfully used by another group when 
toxicities occur [1,7]. 
 
Hypertension and proteinuria are known adverse events associated with bevacizumab 
therapy in malignant disease [14] and in NF2 [3,15,4,6].  In addition, hypertension is 
more common in NF2 than in the general population.  While age is a coexistent risk 
factor, even young patients with NF2 develop hypertension more frequently than age 
matched controls [16].   
 
Bevacizumab is currently the only effective medical agent available for treating NF2-
associated tumours.  The impact on long-term health of hypertension and proteinuria 
and other bevacizumab-related toxicities are yet to be determined.   
 
In this paper we present the adverse events in the UK NF2 bevacizumab cohort, the 
largest NF2 cohort to date, with particular attention to cardiac and renal adverse 
events. 
 
Methods:   
1) Study Cohort 
The clinical records of 80 NF2 patients who commenced treatment with bevacizumab 
between August 2010 and November 2014 according to the UK national protocol 
were reviewed [6].  Bevacizumab treatment dose and the presence of any adverse 
events were recorded at each cycle of treatment alongside the need for any break in 
treatment. The following data were also collected: genetic severity [6], personal or 
family history of hypertension, concurrent medications, Body Mass Index (BMI) at 
baseline and smoking history. Mean arterial pressure (MAP) at infusion clinic and 
creatinine clearance (CrCl) calculated according to the Cockcroft-Gault equation were 
recorded over time. Data continued to be collected if the patient discontinued 
treatment. 
 
2) Adverse events 
All adverse events were recorded and classified according the Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03 [17].   Hypertension according to 
NICE and AHA guidelines is defined as a blood pressure of ≥140/90 mmHg on 
repeated measures and this definition corresponds to a CTCAE grade 2 event [18,17].  
CTCAE grade 1 hypertension is equivalent to pre-hypertension. In this study, a 
proteinuria event was defined as either 1+ proteinuria (CTCAE grade 1) on 3 
consecutive recordings or CTCAE grade 2 (2+ proteinuria, 1.0-3.4 g /24 hours 
proteinuria or proten:creatinine ratio 0.5-1.9) or CTCAE grade 3 (≥3.5g /24hours 
proteinuria or protein:creatinine ratio > 1.9).  
 
Analysis of the time and cumulative bevacizumab dose to first event for development 
of CTCAE ≥ grade 2 hypertension and proteinuria were performed.   
 
3) Statistical analysis 
Statistical analysis was performed using SPSS version 23 (IBM).  A Kaplan-Meier 
analysis of time to first hypertension or proteinuria event was undertaken for patients 
who had completed 12, 24 and 36 months of follow-up respectively. Bivariate 
Pearson’s correlations were used to examine correlations between baseline 
characteristics, initial dosing regime (5mg/kg two weekly or 7.5mg/kg three weekly), 
cumulative bevacizumab dose, volumetric treatment response of the index tumour and 
the development of hypertension and proteinuria. An analysis of smoking history was 
performed with a binary grouping (current or previous smoker versus never having 
smoked).   
Logistic regression models to identify predictors for the development of hypertension 
and proteinuria were subsequently performed using a Chi Square test of significance 
and Nagelkerke calculation of the R square statistic.  
Longitudinal change in MAP and Cr Cl were assessed by analysis of marginal means 
over time. 
 
Results:  
The baseline characteristics of the cohort are shown in Table 1.  The median follow-
up and median duration of bevacizumab treatment were 32.7 months (range 12.0 – 
60.2 months) and 27.4 months (range 3 - 58.6 months) respectively.  Patients received 
an induction dose of 5mg/kg two weekly in 55/80 for a median of 6.9 months (range 
3-41.7 months) and 7.5mg/kg three weekly in 25/80 for a median of 7.6 months 
(range 1.6-31.1 months); including 8 patients (6 patients on 5mg/kg two weekly and 2 
patients on 7.5mg/kg three weekly) who did not drop to maintenance dose (2.5-
5mg/kg 4 weekly) for the duration of their treatment at the discretion of their treating 
physician (median 15.9 months; range 3-42.7 months). The median total dose per 
kilogram was 166.25mg/kg (range 40 – 615 mg/kg).  
 
There were 62 breaks in treatment in 41 patients with median treatment break 
duration of 3 months (range 1-15.5 months).  This gave a corrected median duration 
of exposure to bevacizumab of 24 months (range 3-53.5 months).   The reasons for 
breaks in treatment were adverse events in 24/62, surgical or dental procedures in 
23/62, accidental injury in 7/62, non-response in 2/62, social in 4/62 and stable 
disease in 2/62. Twenty-one patients were followed up after cessation of treatment for 
a median duration of 10 months (range 2 – 19 months).   
 
Adverse events 
All of the adverse events recorded during treatment are summarised in Table 2.  The 
most common adverse events were fatigue, hypertension and infection. A total of 580 
events were recorded from 73 patients.  There were no bevacizumab associated 
deaths. Breaks in treatment due to the development of either hypertension or 
proteinuria occurred in nine (11%) and six (7.5%) patients respectively. One patient 
developed significant left ventricular heart failure whilst on treatment and this case is 
described in detail below.  
 
The Development of Hypertension and Proteinuria  
During treatment and follow-up off treatment a total of 19/80 patients (24%) had at 
least one CTCAE grade 2 (18/80) or CTCAE grade 3 hypertension event (6/80) and 
14/80 patients (17.5%) had a proteinuria event.  A break in treatment (missing at least 
one dose) occurred due to a hypertension or proteinuria event in 9/19 and 6/14 of 
these patients respectively. Six additional patients had a CTCAE grade 1 hypertension 
event and 14 patients had a single 1+ proteinuria event. No grade 3 proteinuria events 
occurred. 
 
Kaplan-Meier survival analyses for the development of grade 2 or 3 hypertension or 
proteinuria in patients who had completed 12, 24 and 36 months of follow-up are 
shown in Table 3. The survival curves for the development of hypertension or 
proteinuria to 24 months from start of treatment are shown in Figure 1. 
 
The median time and dose per kg to first grade 2 or above hypertensive event were 
2.7 months (range 0 - 33 months) and 30mg/kg (range 7.5 - 202.5 mg/kg) 
respectively.    
 
The median time and dose to first proteinuria event were 10.7 months (range 3 - 36 
months) and 85mg/kg (range 30 - 237.5 mg/kg) respectively.  
 
Bivariate relationships with development of grade 2 or above hypertension were 
analysed and found age (p<0.001) and dosing regimen (p=0.004) to be significant.  
Logistic regression was then performed with hypertension as the dependent variable 
and age, gender, proteinuria and initial dose regime as predictor (independent) 
variables.   The model Nagelkerke R square was 0.208, model p value < 0.001 with 
significant predictors being increasing age and initial dose regime. The rates of 
hypertension were 4% in the under 20 year old group, 16% in the 20-29 year old 
group and 50% in the group ≥ 30 years old at the start of treatment.  The number of 
patients per decade of age who developed hypertension is shown in Figure 2. 
Increased events were seen in the 7.5mg/kg three weekly group where 36% (10/25) 
developed hypertension compared to 16% (9/55) in the 5mg/kg two weekly group. 
Gender, genetic severity, smoking history, family history and total dose were not 
associated with the development of hypertension.  
 
Proteinuria and hypertension co-existed in 7/14 patients but a correlation between 
hypertension and proteinuria did not reach statistical significance (r=0.21, p=0.07). 
 
Only a family history of hypertension and a positive smoking history were found to 
be independent predictors of proteinuria on a logistic regression analysis with 
dependent variable proteinuria and independent variables age, smoking history, 
family history (Nagelkerke R square = 0.25, p value < 0.001).   
 
Volumetric schwannoma response data was available in 46/80 patients [6].  In this 
subgroup no relationship was identified between volumetric imaging response and the 
development of either hypertension (p=0.09) or proteinuria (p= 0.13). 
  
Hypertension and proteinuria after cessation of treatment 
Twenty-one patients stopped treatment and were followed up for a median of 10 
months (range 3-20 months) after their final dose of bevacizumab.  This was elective 
discontinuation in 14/21 patients. Seven of 21 patients discontinued treatment due to 
an adverse event; 3 with proteinuria events; one each of infection, cardiac, creatinine 
elevation in the context of cyclophosphamide for a second condition and hepatobilary 
toxicity.  These final four patients did not have hypertension or proteinuria throughout 
follow-up.  
 
Two patients who stopped electively had developed hypertension during bevacizumab 
treatment and commenced anti-hypertensive medication.  One of these patients (age 
39 years) who completed 34 months of treatment remains on anti-hypertensive 
medication 8 months post treatment cessation. The second patient (age 27 years) who 
completed 23 months of bevacizumab treatment experienced a normalisation of their 
blood pressure after cessation of treatment and was able to discontinue treatment with 
an anti-hypertensive agent at 9 months after cessation of bevacizumab.   
 
In the remaining 12 patients who stopped treatment electively after a median of 35 
months (range 12-60 months), there were no significant hypertension or proteinuria 
events during treatment or follow up after cessation of treatment. 
 
Three patients ceased treatment due to proteinuria. One patient (age 11 years) had 12 
months off treatment following a grade 2 proteinuria event. Before recommencing 
treatment for ongoing tumour growth the patient had 1+ proteinuria that occurred 
intermittently on re-treatment with bevacizumab.  After a further 8 months of 
treatment with bevacizumab, 2+ proteinuria recurred although urinary 
protein:creatinine ratio was normal. The second patient (age 58 years) developed 
grade 2 proteinuria with an elevated albumin:creatinine ratio after 6 months of 
treatment.  This patient had developed hypertension and commenced amlodipine after 
1 month of treatment. At 9 months follow-up from cessation of bevacizumab (15 
months after initial commencement of treatment), blood pressure was normal and the 
urine albumin:creatinine ratio had improved but remained elevated.  The third patient 
(age 47 years) developed hypertension within the first month of treatment and 
commenced ramipril and amlodipine.   After 17 months of treatment with 
bevacizumab, proteinuria developed with an elevated albumin:creatinine ratio and 
bevacizumab treatment was ceased.  After 10 months off treatment proteinuria was no 
longer detected. 
 
Modeling of mean arterial pressure and creatinine clearance over time 
In all patients with available MAP from every cycle of treatment and 6 monthly 
creatinine clearance, linear modeling of mean arterial pressure (n=20) and creatinine 
clearance (n=62) over time did not show significant change in either measure over 
time. 
 
Case of dilated cardiomyopathy presenting with palpitations and dizziness 
A 19 year old male commenced treatment with bevacizumab for a growing left 
vestibular schwannoma at 5 mg/kg two weekly for 6 months then decreased to a 
maintenance dose of 5mg/kg four weekly. His history of NF2 included previous 
resections of longitudinally extensive cervical spine ependymoma (C4 –T3) at ages 15 
and 18, adjuvant radiotherapy to the ependymoma age 18 and deafness on the right 
secondary to a vestibular schwannoma (VS).  After 15 months of bevacizumab 
treatment, the left VS was stable but the right VS continued to grow. Treatment was 
suspended for 6 months and the right VS resected and an Auditory Brainstem Implant 
(ABI) fitted; After a further 24 months of 5mg/kg four weekly bevacizumab (39 
months from the initial start of treatment), treatment was ceased after an episode of 
palpitations and pallor.  Electrocardiogram demonstrated left bundle branch block and 
echocardiogram demonstrated left ventricular dysfunction with an ejection fraction of 
less than 35% in the context of a previously normal echocardiogram prior to 
commencement of bevacizumab.  He was commenced on bisoprolol, ramipril and 
spironolactone. A myocardial perfusion scan raised the possibility of filling defects in 
keeping with possible previous myocardial infarction but there was no evidence of 
reversible ischaemia. After 12 months off bevacizumab and whilst continuing 
bisoprolol and ramipril cardiac MRI demonstrated that all coronary territories were 
viable with no focal myocardial scarring or fibrosis and good left ventricular function.  
An echocardiogram 5 years after initially commencing bevacizumab and 20 months 
after cessation of bevacizumab showed low normal left ventricular ejection fraction. 
He has had no further palpitations or breathlessness and medications for heart failure 
are to be withdrawn.  The patient never had a documented episode of hypertension 
and did not experience any other adverse events. 
 
Discussion: 
While the majority of bevacizumab toxicity events in NF2 patients are low grade, the 
risk of hypertension and proteinuria remains a concern in this population of young 
patients requiring prolonged treatment with bevacizumab. The persistence of an 
abnormal albumin:creatinine ratio in one of the patients nine months following 
treatment cessation implies long-term nephrotoxicity is a significant concern. Renal 
biopsy reports in patients with bevacizumab associated proteinuria are sparse but the 
most commonly described change is of glomerular thrombotic microangiopathic 
change [19]. As NF2 patients have a higher rate of hypertension than age matched 
controls, exposure to bevacizumab may further increase that risk and this may account 
for why rates are similar to older general oncology populations [16]. 
 Hypertension in our cohort appears to be an early event that may be related to patient 
factors, particularly age, rather than total dose exposure. Conversely, proteinuria often 
occurs much later in disease course, and is not necessarily preceded by hypertension.  
This variation in timing of events may be due to the proposed mechanism of 
hypertension and proteinuria in VEGF inhibition.  Hypertension is thought to be at 
least in part mediated by decreases in nitric oxide pathways while disruption of 
podocytes and increased glomerular permeability may lead to proteinuria [14]. As 
with previous reports in NF2, aside from age, conventional risk factors for 
hypertension were not identified as independent risk factors for hypertension in our 
cohort.  
 
Slusarz et al.[15] utilized single blood pressure recordings from infusion records to 
track the development of hypertension in NF2 patients while treated with 
bevacizumab.  This has a risk of over estimation of hypertension. We used diagnostic 
criteria according to NICE, AHA and CTCAE definitions that require documentation 
of hypertension on repeated measures.  However, in addition, part of the increase in 
hypertension rate in their cohort (15/26 patients, 58%) in comparison to our group 
may be the use of higher doses throughout treatment.  However, we identified a 
higher rate of hypertension when using a dose of 7.5mg/kg three weekly than 2/14 
patients reported in the cohort described by Blakely et al [8].  Both our group and case 
reports from others have demonstrated a protocol including a reduction in dose 
density and frequency can continue to provide control over tumour size [6,7]. In a 
case described Farschtschi et al. a patient who developed hypertension (equivalent to 
CTCAE grade 3 definition) had a break from bevacizumab and then restarted at a 
lower dose of 2.5mg/kg three weekly had no further hypertension [7]. However, in a 
meta-analysis of non-NF2 studies suggesting an increased risk of proteinuria and 
hypertension with high versus low dose bevacizumab, doses of up to 7.5mg/kg per 
dose were all considered low dose [20].  Our finding of a correlation between dose 
intensity during the induction treatment phase and development of hypertension may 
be consistent with this.  
 
Slusarz et al describe a sequential development of proteinuria from none to 3+ 
proteinuria.  This was not observed in our cohort.  Particularly 1+ proteinuria can 
have multiple aetiologies and did not precede 2+ proteinuria in the majority of our 
cases.   
 
Correlations between the development of hypertension and proteinuria have been 
described in the general oncology literature.  These have not been replicated in our 
study or another previously described small NF2 cohort [15].  The size of the groups 
observed on bevacizumab with NF2 may have been too small to identify any 
relationship that may exist between the risk of these two events.  The relationship 
between tumour response to treatment and development of hypertension or 
proteinuria has only been identified by some groups and not others.   
 
Importantly, we describe the first reported case of left ventricular failure in a patient 
with NF2 treated with bevacizumab.  This event is particularly notable due to young 
age, lack of hypertension or previous exposure to cardiotoxic drugs.  Congestive heart 
failure (CHF) associated with bevacizumab has been described in other oncology 
settings at a rate of 2-4% in some breast cancer trials but not in retrospective review 
of over 6000 patients treated for colorectal cancer.  Previous exposure to cardiotoxic 
drugs such as anthracyclines, or to radiation, has been suggested as the main 
predisposing factor rather than advancing age or other risk factors for development of 
CHF [21].  However, a VEGF inhibitor specific mechanism, particularly in the 
context of hypertension and potential vascular remodeling has been suggested [22].  
Our case raises the possibility of a VEGF inhibition specific mechanism for the 
development of left ventricular failure in patients exposed to bevacizumab. 
 
Our study has shown that further work is required to determine the optimal dosing 
regimes for NF2 patients receiving bevacizumab to minimise potentially serious 
toxicity without impacting on efficacy.  Such strategies could potentially include a 
reduction in dose intensity during treatment induction and the consideration of lower 
maintenance does and drug holidays in patients who are likely to be on long-term 
treatment. While induction doses of 5mg/kg two weekly and 7.5mg three weekly have 
been previously viewed as equivalent, it may be necessary to reconsider this in light 
of the observed differences in hypertension rates observed. 
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Legends: 
Figure 1: Kaplan-Meier analysis of hypertension (HTN) and proteinuria of n=55 
patients 24 months from start of treatment 
Figure 2:  The patients per decade age group who developed hypertension (grade 2 or 
above) whilst on treatment with bevacizumab. Blue= no hypertension, Red = 
developed grade ≥2 hypertension. 
Table 1:  Baseline characteristics of cohort (n=80).  
*One patient declined genetic testing, numbers rounded. 
Table 2: The frequency of adverse events categorized by CTCAE grade. The % refers 
to the whole patient cohort (n=80) except for menstrual changes which are calculated 
as a proportion of female patients only (n=32).  Blank cells denote no adverse event. 
^ Previous background of depressive illness. Psychotic event thought to be secondary 
to this rather than bevacizumab exposure. *Seizure suspected to be secondary to 
infection rather than bevacizumab exposure.   
Table 3: Survival proportions as a percentage of the study cohort available for 
analysis of hypertension and proteinuria end points at 12 (n=80), 24 (n=55) and 36 
(n=36) months from start of treatment (Kaplan-Meier analysis). 
  
Table 1:   
Median age  (range) 24.5 (11-66) years 
Number of patients per age bracket   
<20 years 28 
20-29 years 27 
30-39 years 12 
40-49 years 6 
≥50 years 7 
Gender M:F (% male) 48:32 (60%) 
Median BMI (range) 23.3 (15.3-30.2) kg/m2 
Family history of hypertension: n (%) 8 (10%) 
Positive smoking history: n (%)  15 (19%) 
Genetic severity (%)*   
Mild 25% 
Moderate 30% 
Severe 44% 
 
Table 2:  
Adverse event 
Grade 1 Grade 2 Grade 3 Grade 4 
Events Patients % Cohort Events Patients % Cohort Events Patients % Cohort Events Patients % Cohort 
Hypertension 13 9 11% 32 18 23% 14 6 8%       
Infection 8 7 9% 44 16 20% 4 3 4% 2 2 3% 
Proteinuria 62 28 35% 24 14 18%            
Fatigue 85 30 38% 15 9 11% 1 1 1%      
Pain 5 5 6% 9 7 9%            
Mucositis 40 16 20% 11 6 8%            
Nausea 33 14 18% 4 3 4%            
Menorrhagia 3 3 9% 3 3 9% 1 1 3%      
UTI       3 3 4%            
Constipation 9 6 8% 4 2 3%            
Rash 6 6 8% 2 2 3% 1 1 1%      
Ulceration 6 5 6% 4 2 3%            
Delayed wound healing 4 4 5% 2 2 3% 1 1 1%      
Hepatobiliary Disorder 4 3 4% 2 2 3% 1 1 1%      
Vomiting 5 3 4% 3 2 3%            
Diarrhoea 32 11 14% 1 1 1%            
Irregular Menses 8 6 19% 6 1 3%            
Depression 3 2 3% 1 1 1%       1 1 1% 
Haematuria 3 2 3% 1 1 1%            
Hyperkalemia 4 2 3% 4 1 1% 1 1 1%      
Periodontal disease 4 2 3% 1 1 1%            
Arthralgia       2 1 1%            
Epistaxis 15 11 14%                  
Headache 3 3 4%                   
Rectal bleeding 3 3 4%                   
Creatinine elevation 2 2 3%                   
Dizziness 4 2 3%                   
Haemoglobin (elevated) 4 1 1%                   
Palpitations 1 1 1%                   
Heart failure       1 1 1%    
Renal function change 1 1 1%                   
Thrombocytopenia 1 1 1%             1 1 1% 
Psychosis             1^ 1 1%       
Seizure                   1* 1 1% 
Table 3:  
  
Survival proportions (%) 
12 months  24 months 36 months 
Hypertension 81% 76% 78% 
Proteinuria 90% 87% 86% 
 
 
 
 
 
 
